Rhodiola Rosea: Adaptogen Evidence Review for Fatigue and Stress
Rhodiola has multiple RCTs for stress-induced fatigue and cognitive performance. This review explains the evidence quality, standardisation requirements, and comparison to ashwagandha.
Quick Answer
Rhodiola rosea has moderate evidence for reducing fatigue in people under stress and improving cognitive performance during mentally demanding tasks. It works faster than ashwagandha (effects within 1–2 weeks) but the evidence base is smaller and several trials have significant limitations.
Key Takeaways
- 01---
- 02The pharmacologically active components in rhodiola are:
- 03**Rosavins** (including rosavin, rosin, rosarin) — unique to *R. rosea*
- 04**Salidroside** (p-tyrosol glucoside) — also found in other plants
- 05Standardised extracts are typically 3% rosavins and 1% salidroside. Products without standardisation percentages on the label have unverifiable potency.
Quick Answer
Rhodiola rosea has moderate evidence for reducing fatigue in people under stress and improving cognitive performance during mentally demanding tasks. It works faster than ashwagandha (effects within 1–2 weeks) but the evidence base is smaller and several trials have significant limitations. Standardisation to rosavin and salidroside content is essential.
Active Compounds and Standardisation
The pharmacologically active components in rhodiola are:
- Rosavins (including rosavin, rosin, rosarin) — unique to R. rosea
- Salidroside (p-tyrosol glucoside) — also found in other plants
Standardised extracts are typically 3% rosavins and 1% salidroside. Products without standardisation percentages on the label have unverifiable potency.
Mechanism of Action
Rhodiola appears to work primarily through:
- Modulation of stress hormones (cortisol, catecholamines)
- Monoamine neurotransmitter system effects (serotonin, dopamine precursor reuptake inhibition)
- HIF-1α pathway modulation (cellular oxygen utilisation)
- Neuroprotective antioxidant effects
Unlike ashwagandha's primarily GABAergic calming mechanism, rhodiola has mild stimulant-adjacent properties — it tends to energise rather than sedate.
Evidence Review
Fatigue: A 2009 RCT (n=60, double-blind) in burned-out physicians found 170 mg/day of SHR-5 extract significantly reduced fatigue and cognitive dysfunction scores over 4 weeks. A 2012 open-label study in 480 stressed individuals found similar improvements over 4 weeks.
Cognitive performance: A 2003 double-blind crossover trial (n=56 young physicians on night shift) found single dose 170 mg rhodiola significantly improved mental fatigue and task-related attention errors.
Anxiety: A 2015 RCT (n=80) compared rhodiola to sertraline and placebo over 12 weeks in mild-to-moderate depression. Rhodiola produced smaller but more tolerable effects than sertraline.
Evidence Summary
| Outcome | Evidence Level | Notes |
|---|---|---|
| Stress-related fatigue | Moderate | Multiple RCTs |
| Cognitive performance under stress | Moderate | Particularly acute effects |
| Exercise performance | Preliminary | Inconsistent |
| Depression (mild-moderate) | Preliminary | 1 RCT vs sertraline; underpowered |
| Anxiety | Preliminary | Limited direct trials |
Rhodiola vs Ashwagandha
| Rhodiola | Ashwagandha | |
|---|---|---|
| Primary effect | Energising adaptogen | Calming adaptogen |
| Onset | Days–1 week | 4–8 weeks |
| Evidence strength | Moderate | Moderate |
| Cortisol effect | Acute blunting | Longer-term reduction |
| Best use | Mental fatigue, acute performance | Chronic stress, sleep, sustained anxiety |
Many people combine both; the mechanisms are largely complementary.
Dosage Reference
| Use | Dose | Timing |
|---|---|---|
| Fatigue, cognitive support | 200–400 mg/day (standardised) | Morning or before demanding tasks |
| Acute use | 200 mg 1–2 hours before event | Single dose |
| Cycling | 8 weeks on, 2 weeks off | Anecdotally recommended; limited data |
Taking rhodiola late in the day may affect sleep in some people due to its mild stimulant properties.
Safety Notes
- Well-tolerated at studied doses; most side effects are mild and include dizziness and dry mouth.
- May interact with CYP3A4 substrates — some drug metabolism potential.
- Avoid in bipolar disorder (theoretical mania risk from stimulant-adjacent effects).
- Quality control is a significant issue in the rhodiola market; many products contain little to no verified rosavins. Third-party testing is important.
FAQ
Frequently Asked Questions
Medically reviewed
Last reviewed May 9, 2026 by Migaku Editorial Team
Related content